The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
Open accessAbstract
// David M. Goldenberg 1, 2 , Rhona Stein 1 and Robert M. Sharkey 1, 3 1 Center for Molecular Medicine and Immunology, Belleville, NJ, USA 2 IBC Pharmaceuticals, Inc., Morris Plains, NJ, USA 3 Immunomedics, Inc., Morris Plains, NJ, USA Correspondence to: David M. Goldenberg, email: dmg.gscancer@att.net Keywords: TROP-2; TACSTD2; sacituzumab govitecan; antibody-drug conjugates; immunotherapy Received: April 30, 2018 Accepted: May 31, 2018 Published: June 22, 2018 ABSTRACT TROP-2 is a glycoprotein first described as a surface marker of trophoblast cells, but subsequently shown to be increased in many solid cancers, with lower expression in certain normal tissues. It regulates cancer growth, invasion and spread by several signaling pathways, and has a role in stem cell biology and other diseases. This review summarizes TROP-2’s properties, especially in cancer, and particularly its role as a target for antibody-drug conjugates (ADC) or immunotherapy. When the irinotecan metabolite, SN-38, is conjugated to a humanized anti-TROP-2 antibody (sacituzumab govitecan), it shows potent broad anticancer activity in human cancer xenografts and in patients with advanced triple-negative breast, non-small cell and small-cell lung, as well as urothelial cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a Cell of Origin for Human Prostate Cancer
Goldstein, A. S., Huang, J., Guo, C., Garraway, I. P., & Witte, O. N. (2010) · Science · doi:10.1126/science.1189992 · Cited by 554
The biology of the 17–1A antigen (Ep-CAM)
Balzar, M., Winter, M. J., de Boer, C. J., & Litvinov, S. V. (1999) · Journal of Molecular Medicine · doi:10.1007/s001099900038 · Cited by 545
Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4318 · Cited by 495
Self-citationReview: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management
Stein, A., Voigt, W., & Jordan, K. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009355164 · Cited by 431
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Xu, Y., & Villalona-Calero, M. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf337 · Cited by 413
Bardia, A., Mayer, I. A., Diamond, J. R., Moroose, R. L., Isakoff, S. J., Starodub, A. N., Shah, N. C., O’Shaughnessy, J., Kalinsky, K., Guarino, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.8297 · Cited by 412
Self-citationTrop2 and its overexpression in cancers: regulation and clinical/ therapeutic implications
Shvartsur, A., & Bonavida, B. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.40 · Cited by 410
Jackson, S. E., & Chester, J. D. (2015) · International Journal of Cancer · doi:10.1002/ijc.28940 · Cited by 369
Starodub, A. N., Ocean, A. J., Shah, M. A., Guarino, M. J., Picozzi, V. J., Vahdat, L. T., Thomas, S. S., Govindan, S. V., Maliakal, P. P., Wegener, W. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3321 · Cited by 340
Self-citationGoldstein, A. S., Lawson, D. A., Cheng, D., Sun, W., Garraway, I. P., & Witte, O. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811411106 · Cited by 340
Upregulation of Trop-2 quantitatively stimulates human cancer growth
Trerotola, M., Cantanelli, P., Guerra, E., Tripaldi, R., Aloisi, A. L., Bonasera, V, Lattanzio, R., Lange, R. D., Weidle, U. H., Piantelli, M., et al. (2013) · Oncogene · doi:10.1038/onc.2012.36 · Cited by 331
Miotti, S., Canevari, S., Ménard, S., Mezzanzanica, D., Porro, G., Pupa, S. M., Regazzoni, M., Tagliabue, E., & Colnaghi, M. I. (1987) · International Journal of Cancer · doi:10.1002/ijc.2910390306 · Cited by 315
Santin, A. D., Zhan, F., Bellone, S., Palmieri, M., Cane, S., Bignotti, E., Anfossi, S., Gokden, M., Dunn, D., Roman, J. J., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20408 · Cited by 313
Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., & Goldenberg, D. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2939 · Cited by 311
Self-citationHuman trophoblast cell-surface antigens defined by monoclonal antibodies.
Lipinski, M., Parks, D. R., Rouse, R. V., & Herzenberg, L. A. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.8.5147 · Cited by 306
Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., Arrojo, R., Liu, D., Rossi, E. A., Chang, C.-H., & Goldenberg, D. M. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00223 · Cited by 304
Self-citationEpCAM: Structure and function in health and disease
Schnell, U., Cirulli, V., & Giepmans, B. N. G. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.04.018 · Cited by 289
Potential hepatic stem cells reside in EpCAM+ cells of normal and injured mouse liver
Okabe, M., Tsukahara, Y., Tanaka, M., Suzuki, K., Saito, S., Kamiya, Y., Tsujimura, T., Nakamura, K., & Miyajima, A. (2009) · Development · doi:10.1242/dev.031369 · Cited by 287
Stepan, L. P., Trueblood, E. S., Hale, K., Babcook, J., Borges, L., & Sutherland, C. L. (2011) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155411410430 · Cited by 271
Ocean, A. J., Starodub, A. N., Bardia, A., Vahdat, L. T., Isakoff, S. J., Guarino, M., Messersmith, W. A., Picozzi, V. J., Mayer, I. A., Wegener, W. A., et al. (2017) · Cancer · doi:10.1002/cncr.30789 · Cited by 244
Self-citationBreast Cancer Resistance Protein Directly Confers SN-38 Resistance of Lung Cancer Cells
Kawabata, S., Oka, M., Shiozawa, K., Tsukamoto, K., Nakatomi, K., Soda, H., Fukuda, M., Ikegami, Y., Sugahara, K., Yamada, Y., et al. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4267 · Cited by 242
Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates
Sharkey, R. M., & Goldenberg, D. M. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.4.226 · Cited by 242
Self-citationTrop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway
Cubas, R., Zhang, S., Li, M., Chen, C., & Yao, Q. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-253 · Cited by 232
Soverini, S., Mancini, M., Bavaro, L., Cavo, M., & Martinelli, G. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0780-6 · Cited by 222
Trop-2 Is a Determinant of Breast Cancer Survival
Ambrogi, F., Fornili, M., Boracchi, P., Trerotola, M., Relli, V., Simeone, P., La Sorda, R., Lattanzio, R., Querzoli, P., Pedriali, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096993 · Cited by 221
Human TROP-2 is a tumor-associated calcium signal transducer
Rapani, E., Sacchetti, A., Corda, D., & Alberti, S. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980529)76:5<671::aid-ijc10>3.0.co;2-7 · Cited by 220
Identification of the gene responsible for gelatinous drop-like corneal dystrophy
Tsujikawa, M., Kurahashi, H., Tanaka, T., Nishida, K., Shimomura, Y., Tano, Y., & Nakamura, Y. (1999) · Nature Genetics · doi:10.1038/7759 · Cited by 213
Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., McBride, W. J., Sharkey, R. M., & Chang, C.-H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600982103 · Cited by 209
Self-citationHeist, R. S., Guarino, M. J., Masters, G., Purcell, W. T., Starodub, A. N., Horn, L., Scheff, R. J., Bardia, A., Messersmith, W. A., Berlin, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1894 · Cited by 193
Self-citationTrop2: A possible therapeutic target for late stage epithelial carcinomas
Cubas, R., Li, M., Chen, C., & Yao, Q. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.08.001 · Cited by 192
Stoyanova, T., Cooper, A. R., Drake, J. M., Liu, X., Armstrong, A. J., Pienta, K. J., Zhang, H., Kohn, D. B., Huang, J., Witte, O. N., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320565110 · Cited by 176
Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2.
Szala, S., Froehlich, M., Scollon, M., Kasai, Y., Steplewski, Z., Koprowski, H., & Linnenbach, A. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.9.3542 · Cited by 173
Sharkey, R. M., McBride, W. J., Cardillo, T. M., Govindan, S. V., Wang, Y., Rossi, E. A., Chang, C.-H., & Goldenberg, D. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0670 · Cited by 172
Self-citationThe Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics
Anders, C. K., Abramson, V. G., Tan, T. J., & Dent, R. A. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159135 · Cited by 172
Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis
Zeng, P., Chen, M.-B., Zhou, L.-N., Tang, M., Liu, C.-Y., & Lu, P.-H. (2016) · Scientific Reports · doi:10.1038/srep33658 · Cited by 163
Gray, J. E., Heist, R. S., Starodub, A. N., Camidge, D. R., Kio, E. A., Masters, G. A., Purcell, W. T., Guarino, M. J., Misleh, J., Schneider, C. J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0933 · Cited by 162
Self-citationAntibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy
Moon, S.-J., Govindan, S. V., Cardillo, T. M., D’Souza, C. A., Hansen, H. J., & Goldenberg, D. M. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800719t · Cited by 159
Self-citationThe Trop-2 signalling network in cancer growth
Guerra, E., Trerotola, M., Aloisi, A. L., Tripaldi, R., Vacca, G., Sorda, R. L., Lattanzio, R., Piantelli, M., & Alberti, S. (2012) · Oncogene · doi:10.1038/onc.2012.151 · Cited by 149
Cloning of the gene encoding TROP‐2, a cell‐surface glycoprotein expressed by human carcinomas
Fornaro, M., Arciprete, R. D., Stella, M., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620520 · Cited by 149
Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers
Wang, J., Day, R. B., Dong, Y., Weintraub, S. J., & Michel, L. S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2003 · Cited by 145
Liu, T., Liu, Y., Bao, X., Tian, J., Liu, Y., & Yang, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075864 · Cited by 144
Cardillo, T. M., Sharkey, R. M., Rossi, D. L., Arrojo, R., Mostafa, A. A., & Goldenberg, D. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2401 · Cited by 133
Self-citationTrop-2 Promotes Prostate Cancer Metastasis By Modulating β1 Integrin Functions
Trerotola, M., Jernigan, D. L., Liu, Q., Siddiqui, J., Fatatis, A., & Languino, L. R. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3266 · Cited by 129
Park, J. W., Lee, J. K., Phillips, J. W., Huang, P., Cheng, D., Huang, J., & Witte, O. N. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603645113 · Cited by 128
Sequence investigation of the major gastrointestinal tumor-associated antigen gene family, GA733.
Linnenbach, A. J., Wojcierowski, J., Wu, S., et al. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.1.27 · Cited by 126
Trop2: From development to disease
McDougall, A. R. A., Tolcos, M., Hooper, S. B., Cole, T. J., & Wallace, M. J. (2014) · Developmental Dynamics · doi:10.1002/dvdy.24242 · Cited by 125
Nakashima, K., Shimada, H., Ochiai, T., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20517 · Cited by 120
TROP2 is epigenetically inactivated and modulates IGF‐1R signalling in lung adenocarcinoma
Lin, J., Wu, Y., Wu, J., Lin, T., Wu, C., Chang, Y., Jou, Y., Hong, T.-M., & Yang, P. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200222 · Cited by 117
Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea
Xie, R., Mathijssen, R. H. J., Sparreboom, A., Verweij, J., & Karlsson, M. O. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.126741 · Cited by 116
Lin, H., Huang, J., Qiu, J., Zhang, H., Tang, X., Li, H., Wang, C., Wang, Z.-C., Feng, Z., & Zhu, J. (2012) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2012.08.004 · Cited by 109
Faltas, B. M., Goldenberg, D. M., Ocean, A. J., Govindan, S. V., Wilhelm, F. E., Sharkey, R. M., Hajdenberg, J. J., Hodes, G., Nanus, D. M., & Tagawa, S. T. (2015) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2015.10.002 · Cited by 106
Self-citationEpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer
Schneck, H., Gierke, B., Uppenkamp, F., Behrens, B., Niederacher, D., Stoecklein, N. H., Templin, M. F., Pawlak, M., Fehm, T. N., Neubauer, H. J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144535 · Cited by 106
Strop, P., Tran, T.-T., Dorywalska, M., Delaria, K., Dushin, R. G., Wong, O. K., Ho, W.-H., Zhou, D., Wu, A., Kraynov, E. A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0431 · Cited by 105
Clinical Pharmacokinetics of Irinotecan and Its Metabolites: A Population Analysis
Xie, R., Mathijssen, R. H. J., Sparreboom, A., Verweij, J., & Karlsson, M. O. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.073 · Cited by 101
Retroposition in a Family of Carcinoma-Associated Antigen Genes
Linnenbach, A. J., Seng, B. A., Wu, S., Robbins, S. M., Scollon, M., Pyrc, J. J., Druck, T., & Huebner, K. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.3.1507 · Cited by 98
Nakatsukasa, M., Kawasaki, S., Yamasaki, K., Fukuoka, H., Matsuda, A., Tsujikawa, M., Tanioka, H., Nagata-Takaoka, M., Hamuro, J., & Kinoshita, S. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100149 · Cited by 91
Li, X., Teng, S., Zhang, Y., Zhang, W., Zhang, X., Xu, K., Yao, H., Yao, J., Wang, H., Liang, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16789 · Cited by 91
A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo
Lin, H., Zhang, H., Wang, J., Lu, M., Zheng, F., Wang, C., Tang, X., Xu, N., Chen, R., Zhang, D., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28451 · Cited by 90
Basu, A., Goldenberg, D. M., & Stein, R. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620419 · Cited by 89
Self-citationHuang, H., Groth, J., Sossey‐Alaoui, K., Hawthorn, L., Beall, S. A., & Geradts, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2107 · Cited by 89
Stein, R., Basu, A., Chen, S. E., et al. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550611 · Cited by 89
Self-citationTNF-α promotes colon cancer cell migration and invasion by upregulating TROP-2
Zhao, P., & Zhang, Z. (2018) · Oncology Letters · doi:10.3892/ol.2018.7735 · Cited by 87
King, G. T., Eaton, K. D., Beagle, B. R., Zopf, C. J., Wong, G. Y., Krupka, H. I., Hua, S. Y., Messersmith, W. A., & El-Khoueiry, A. B. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0560-6 · Cited by 87
El-Sewedy, T., Fornaro, M., & Alberti, S. (1998) · International Journal of Cancer · Cited by 82
Nakanishi, H., Taccioli, C., Palatini, J., Fernandez-Cymering, C., Cui, R., Kim, T., Volinia, S., & Croce, C. M. (2013) · Oncogene · doi:10.1038/onc.2013.13 · Cited by 80
A Bicistronic CYCLIN D1-TROP2 mRNA Chimera Demonstrates a Novel Oncogenic Mechanism in Human Cancer
Guerra, E., Trerotola, M., Arciprete, R. D., Bonasera, V., Palombo, B., El-Sewedy, T., Ciccimarra, T., Crescenzi, C., Lorenzini, F., Rossi, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6135 · Cited by 80
Chang, C., Rossi, E. A., & Goldenberg, D. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1217 · Cited by 79
Self-citationTrop‐2 inhibits prostate cancer cell adhesion to fibronectin through the β1 integrin‐RACK1 axis
Trerotola, M., Li, J., Alberti, S., & Languino, L. R. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24074 · Cited by 78
Impact of chemotherapy beyond the first line in patients with metastatic breast cancer
Dufresne, A., Pivot, X. B., Tournigand, C., Facchini, T., Altweeg, T., Chaigneau, L., & de Gramont, A. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9550-7 · Cited by 77
Son, S., Shin, S., Rao, N. V., Um, W., Jeon, J., Ko, H., Deepagan, V. G., Kwon, S., Lee, J. Y., & Park, J. H. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.10.113 · Cited by 72
Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts
Trerotola, M., Ganguly, K. K., Fazli, L., Fedele, C., Lu, H., Dutta, A., Liu, Q., De Angelis, T., Riddell, L. W., Riobo, N. A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3960 · Cited by 70
Diversity and Evolution of the Thyroglobulin Type-1 Domain Superfamily
Novinec, M., Kordiš, D., Türk, V., & Lenar≷cic̆, B. (2005) · Molecular Biology and Evolution · doi:10.1093/molbev/msj082 · Cited by 69
The biology of signal transduction inhibition: Basic science to novel therapies
Griffin, J. D. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90097-1 · Cited by 68
Wang, J., Zhang, K., Grabowska, D., Li, A., Dong, Y., Day, R. B., Humphrey, P. A., Lewis, J. S., Kladney, R. D., Arbeit, J. M., et al. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0241 · Cited by 63
Memarzadeh, S., Zong, Y., Janzen, D. M., Goldstein, A. S., Cheng, D., Kurita, T., Schafenacker, A. M., Huang, J., & Witte, O. N. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012548107 · Cited by 63
Chang, C., Wang, Y., Zalath, M. B., Liu, D., Cardillo, T. M., & Goldenberg, D. M. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0219 · Cited by 62
Self-citationVarughese, J., Cocco, E., Bellone, S., et al. (2011) · Cancer · doi:10.1002/cncr.25891 · Cited by 61
van Rij, C. M., Lütje, S., Frielink, C., Sharkey, R. M., Goldenberg, D. M., Franssen, G. M., McBride, W. J., Rossi, E. A., Oyen, W. J. G., & Boerman, O. C. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2434-7 · Cited by 57
Self-citationIn vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer.
Shih, L. B., Xuan, H., Aninipot, R., Stein, R., & Goldenberg, D. M. (1995) · PubMed · Cited by 53
Self-citationRossi, E. A., Goldenberg, D. M., & Chang, C. (2011) · Bioconjugate Chemistry · doi:10.1021/bc2004999 · Cited by 49
Self-citationVidmar, T., Pavšič, M., & Lenar≷cic̆, B. (2013) · Protein Expression and Purification · doi:10.1016/j.pep.2013.07.006 · Cited by 46
A New Tri-Fab Bispecific Antibody for Pretargeting Trop-2–Expressing Epithelial Cancers
Sharkey, R. M., van Rij, C. M., Karacay, H., Rossi, E. A., Frielink, C., Regino, C. A. S., Cardillo, T. M., McBride, W. J., Chang, C., Boerman, O. C., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.104364 · Cited by 45
Self-citationvan Rij, C. M., Sharkey, R. M., Goldenberg, D. M., Frielink, C., Molkenboer‐Kuenen, J. D. M., Franssen, G. M., van Weerden, W. M., Oyen, W. J. G., & Boerman, O. C. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.086520 · Cited by 42
Self-citationSozo, F., Wallace, M. J., Zahra, V. A., Filby, C. E., & Hooper, S. B. (2005) · Physiological Genomics · doi:10.1152/physiolgenomics.00148.2005 · Cited by 40
A new class of bispecific antibodies to redirect T cells for cancer immunotherapy
Rossi, D. L., Rossi, E. A., Cardillo, T. M., Goldenberg, D. M., & Chang, C. (2013) · mAbs · doi:10.4161/mabs.27385 · Cited by 39
Self-citationOverexpression of TROP2 promotes proliferation and invasion of ovarian cancer cells
Wu, B., Yu, C.-L., Zhou, B., Huang, T., Gao, L., Liu, T., & Yang, X. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4788 · Cited by 39
Liu, Q., Li, H., Wang, Q., Zhang, Y., Wang, W., Dou, S., & Xiao, W. (2016) · Respiratory Research · doi:10.1186/s12931-016-0463-z · Cited by 36
van Rij, C. M., Frielink, C., Goldenberg, D. M., Sharkey, R. M., Lütje, S., McBride, W. J., Oyen, W. J. G., & Boerman, O. C. (2014) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2014.1660 · Cited by 35
Self-citationExpression of the GA733 gene family and its relationship to prognosis in pulmonary adenocarcinoma
Kobayashi, H., Minami, Y., Anami, Y., Kondou, Y., Iijima, T., Kano, J., Morishita, Y., Tsuta, K., Hayashi, S., & Noguchi, M. (2010) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-010-0930-8 · Cited by 35
Liu, D., Cardillo, T. M., Wang, Y., Rossi, E. A., Goldenberg, D. M., & Chang, C. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-53 · Cited by 32
Self-citationZhang, K., Jones, L., Lim, S., Maher, C. A., Adkins, D. R., Lewis, J. S., Kimple, R. J., Fertig, E. J., Chung, C. H., Herrlich, A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2423 · Cited by 31
The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer
Mao, Y., Wang, X., Zheng, F., Wang, C., Tang, Q., Tang, X., Xu, N., Zhang, H., Zhang, D., Xiong, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8529 · Cited by 31
Large and diverse numbers of human diseases with HIKE mutations
Ciccarelli, F. D., Acciarito, A., & Alberti, S. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.6.1001 · Cited by 30
Alberti, S. (1998) · Proteins Structure Function and Bioinformatics · Cited by 29
Mangino, G., Capri, M. G., Barnaba, V., & Alberti, S. (2002) · International Journal of Cancer · doi:10.1002/ijc.10616 · Cited by 29
Xu, P., Zhao, Y., Liu, K., Lin, S., Liu, X., Wang, M., Yang, P., Tian, T., Zhu, Y., & Dai, Z. (2017) · Cancer Management and Research · doi:10.2147/cmar.s147033 · Cited by 27
van Rij, C. M., Frielink, C., Goldenberg, D. M., Sharkey, R. M., Franssen, G. M., Lütje, S., McBride, W. J., Oyen, W. J. G., & Boerman, O. C. (2014) · Molecular Imaging and Biology · doi:10.1007/s11307-014-0772-x · Cited by 26
Self-citationZHAO, P., YU, H.-Z., & CAI, J.-H. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3900 · Cited by 24
Redlich, N. J., Robinson, A. M., Nickel, K. P., Stein, A. P., Wheeler, D. L., Adkins, D. R., Uppaluri, R., Kimple, R. J., Tine, B. A. V., & Michel, L. S. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0029-0 · Cited by 24
Correlation between Trop2 and amphiregulin coexpression and overall survival in gastric cancer
Zhao, W., Ding, G., Wen, J., Tang, Q., Yong, H., Zhu, H., Zhang, S., Qiu, Z., Feng, Z., & Zhu, J. (2017) · Cancer Medicine · doi:10.1002/cam4.1018 · Cited by 23
Radiopharmaceutical therapy in the era of precision medicine
Sgouros, G., & Goldenberg, D. M. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.025 · Cited by 22
Self-citationsiRNA targeting of Trop2 suppresses the proliferation and invasion of lung adenocarcinoma H460 cells
Gao, X., Zhu, Y., ZHANG, L.-X., Lu, H., & Jiang, A.-G. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2530 · Cited by 11
Cardillo, T. M., Mostafa, A. A., Rossi, D. L., Liu, D., Chang, C., Sharkey, R. M., & Goldenberg, D. M. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-3193 · Cited by 8
Self-citationBobos, M., Kotoula, V., Kaloutsi, V. D., Karayannopoulou, G., Papadimitriou, C. S., & Kostopoulos, I. S. (2009) · PubMed · doi:10.14670/hh-24.1035 · Cited by 5
Yang, J., Zhou, Y., Liu, B., Wang, H., & Du, X. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1332 · Cited by 5
Enhancing the antitumor potency of T cells redirected by bispecifc antibodies
Chang, C., & Goldenberg, D. M. (2017) · Oncoscience · doi:10.18632/oncoscience.366 · Cited by 3
Self-citation
Cited by
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814213 · Cited by 874
Self-citationTagawa, S. T., Balar, A. V., Petrylak, D. P., Kalebasty, A. R., Loriot, Y., Fléchon, A., Jain, R. K., Agarwal, N., Bupathi, M., Barthelemy, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03489 · Cited by 543
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Antibody-Drug Conjugate-Based Therapeutics: State of the Science
Birrer, M. J., Moore, K. N., Betella, I., & Bates, R. C. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz035 · Cited by 439
Bardia, A., Messersmith, W. A., Kio, E. A., Berlin, J. D., Vahdat, L., Masters, G. A., Moroose, R., Santin, A. D., Kalinsky, K., Picozzi, V., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.005 · Cited by 400
Self-citation
Metadata
- Authors
- Goldenberg, D. M., Stein, R., & Sharkey, R. M.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2018-06-22
- Volume
- 9
- Issue
- 48
- Pages
- 28989-29006
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2809327804
- Cited by
- 327
- References
- 106
- FWCI
- 10.87
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.